Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adebrelimab + Etoposide Maintenance in ES-SCLC
NCT07141264Phase 2Recruiting
- Sponsor
- Tangdu Hospital
- Start
- Aug 2025
- Primary completion
- Dec 2026
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of adebrelimab in small cell lung cancer (SCLC), sponsored by Tangdu Hospital. Primary endpoint: Progression-Free Survival at 2 years. Started Aug 2025; status: recruiting.
02
Drugs
adebrelimab
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT07141264.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07141264.